---
layout: post
title: "Use of Circulating Tumor Deoxyribonucleic Acid for Early-Stage Solid Tumor Drug Development; Draft Guidance for Industry; Availability"
date: 2026-02-05 18:59:00 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-09459
original_published: 2022-05-03 00:00:00 +0000
significance: 8.00
---

# Use of Circulating Tumor Deoxyribonucleic Acid for Early-Stage Solid Tumor Drug Development; Draft Guidance for Industry; Availability

**Published:** February 05, 2026 18:59 UTC
**Source:** Federal Register
**Original Published:** May 03, 2022 00:00 UTC
**Document Number:** 2022-09459

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Use of Circulating Tumor DNA for Early-Stage Solid Tumor Drug Development." This draft guidance is intended to help sponsors planning to use circulating cell-free plasma derived tumor deoxyribonucleic acid (ctDNA) as a biomarker in cancer clinical trials conducted under an investigational new drug application (IND) and/or to support marketing approval of drugs and biological products for treating solid tumor malignancies in the early-stage setting.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/05/03/2022-09459/use-of-circulating-tumor-deoxyribonucleic-acid-for-early-stage-solid-tumor-drug-development-draft)
- API: https://www.federalregister.gov/api/v1/documents/2022-09459

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
